AOA Dx

AOA Dx · Jun 2026

AOA Dx reported 92% sensitivity for early-stage ovarian cancer detection in symptomatic women at ASCO 2026, alongside 96.5% sensitivity and 80.6% specificity in symptomatic women.

AOA Dx · May 2026

The company enrolled the first participant in a prospective multi-site APEX study in the U.S. and Europe to expand its biobank of symptomatic women.

AOA Dx · Apr 2026

AOA Dx hired Cory Bystrom to advance the platform through clinical validation, CLIA operations, and future FDA submissions.

AOA Dx · Mar 2026

Chris Roberts was appointed Chief Product Officer to lead product strategy, commercialization, and market access for AKRIVIS GD.

AOA Dx · Jan 2026

AOA Dx released its "Follow the Exits" report, estimating more than $100B in realized women’s health exit value across 272 exits between 2000 and 2024.